Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

BTG licenses analgesic combination to Forest

Sep. 6, 1996

FDA approves two pain products from Mallinckrodt

Sep. 6, 1996

NPC-18521, a high-affinity bradykinin B2 receptor antagonist from Scios

Sep. 6, 1996

New introductions for Faulding's sustained-release morphine product

Sep. 6, 1996

Analgesic and antiinflammatory agents superior to capsaicin

Sep. 6, 1996

Lilly's new AMPA antagonist, LY-311446

Aug. 30, 1996

AChE inhibitor isolated from Penicillium at Kitasato Institute

Aug. 30, 1996

PLA2 role in Alzheimer's disease suggested

Aug. 30, 1996

Basic AD research advances reported

Aug. 30, 1996

Pfizer reports new class of muscarinic agonists

Aug. 30, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 27, 2026.
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...